Accentia Biopharmaceuticals, Biovest International, Inc. Shrink Losses, Default on Debt
Published: Dec 27, 2012
Accentia Biopharmaceuticals Inc. and its majority-owned subsidiary, Biovest International Inc., trimmed some of the red ink from their operating statements in fiscal 2012. Accentia (OTCQB: ABPI) reported a loss attributable to common shareholders of $4.3 million, or 5 cents a share, for the year ended Sept. 30, compared to a loss attributable to common shareholders of $11.6 million, or 17 cents a share, in the same period one year ago. Revenue for fiscal 2012 was $4.1 million, a 2.5 percent increase from the prior year. The FY 2012 net loss at Biovest (OTCQB: BVTI) was $11.8 million, or 8 cents a share, compared to a net loss of $15.3 million, or 11 cents a share, in the prior year.